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Abstract: Recent drug discovery efforts have utilized high throughput screening (HTS) of 
large chemical libraries to identify compounds that modify the activity of discrete 
molecular targets. The molecular target approach to drug screening is widely used in the 
pharmaceutical and biotechnology industries, because of the amount of knowledge now 
available regarding protein structure that has been obtained by computer simulation. The 
molecular target approach requires that the structure of target molecules, and an 
understanding of their physiological functions, is known. This approach to drug discovery 
may, however, limit the identification of novel drugs. As an alternative, the phenotypic- or 
pathway-screening approach to drug discovery is gaining popularity, particularly in the 
academic sector. This approach not only provides the opportunity to identify promising 
drug candidates, but also enables novel information regarding biological pathways to be 
unveiled. Reporter assays are a powerful tool for the phenotypic screening of compound 
libraries. Of the various reporter genes that can be used in such assays, those encoding 
secreted proteins enable the screening of hit molecules in both living cells and animals. 
Cell- and animal-based screens enable simultaneous evaluation of drug metabolism or 
toxicity with biological activity. Therefore, drug candidates identified in these screens may 
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have increased biological efficacy and a lower risk of side effects in humans. In this article, 
we review the reporter bioassay systems available for phenotypic drug discovery. 
Keywords:  drug development; high throughput screening; reporter mice; age-related 
disorders 
 
1. Introduction 
Reporter assays have been widely used in biological research [1–3]. Such assays are a powerful 
means of investigating the signaling pathways involved in various biological functions induced by the 
activation of specific transcription factors. The reporter construct usually consists of a promoter 
(enhancer) that drives the transcription of a gene that is easily detected by its activity or expression in 
the assay system. The promoter region binds transcription factors that are activated in response to the 
stimulation of an upstream, receptor-mediated or receptor-independent signaling cascade. Binding of 
the transcription factor to the promoter results in the induction of reporter gene (and subsequent 
reporter protein) expression in response to signaling pathway activation by external stimuli, including 
drug candidates. It is important that the exogenous protein encoded by the reporter gene has unique 
enzymatic activity or another property that distinguishes it from endogenous proteins [4]. 
The activity of the reporter protein is typically assayed by photometry, colorimetry or fluorometry. 
Recently, detection systems based on bioluminescence, chemiluminescence and fluorescence have 
become widely used because of their signal detection sensitivity and ease of use. Improved detection 
equipment, such as charge-coupled device (CCD) cameras, has also enabled the development of 
convenient reporter assay systems for drug screening. There are two major types of reporters, i.e., 
intracellular and extracellular reporters. Intracellular reporter gene products are expressed and retained 
inside the cells. On the other hand, extracellular reporter genes encode proteins that are secreted into 
the medium of cultured cells or the blood stream in animals. Some intra- and extracellular reporter 
gene assays may detect the reporter protein’s activity without killing the cells or animals in which the 
assay is performed. This allows time-course experimentation by sampling of the medium of cultured 
cells, or the blood plasma of research subjects. As such, report bioassays are potentially suitable for 
high throughput screening (HTS) of small molecule drug candidates. Bioassays are used to determine 
the concentration or biological activity of molecules such as hormones, growth factors, and enzymes. 
Moreover, they can be used for measuring the effects of candidate drugs on an organism, cultured 
cells, or recombinant receptors by comparison to gold standard molecules with known target activity. 
The present review provides an overview of the basic properties, efficacies and limitations of protein 
reporter assays, with an emphasis on their application as bioassays for drug screening.  
2. Intracellular Reporters 
2.1. Chloramphenicol Acetyltransferase 
Chloramphenicol  O-acetyltransferase (CAT) has, until recently, been widely used as a reporter 
protein [5]. CAT is a bacterial enzyme that is not expressed in eukaryotes, and it therefore provides a Sensors 2012, 12  
 
 
1650
highly specific detection system. CAT catalyzes the reaction between acetyl-CoA and chloramphenicol 
to form CoA. The CAT assay has been widely used but is difficult to adapt to HTS platforms because 
its activity is not easy to detect directly in cells. 
2.2. β-Galactosidase 
β-Galactosidase (β-Gal) is derived from the bacterial lacZ gene and is widely used as an 
intracellular reporter gene. There are a number of detection options depending on which substrate is 
used. However, β-Gal is affected by endogenous enzymatic activity in most mammalian cells [4]. 
Therefore, it is important to distinguish between the endogenous and exogenous (reporter) enzymes in 
the assay system. This usually requires the pH of the assay mixture to be adjusted, although this may 
not completely eliminate endogenous enzyme activity. Therefore, the utility of β-Gal for HTS assays is 
limited. 
2.3. Luciferase 
Genes encoding luciferase enzymes have been cloned from several species, including firefly and sea 
pansy [1]. Firefly luciferase catalyzes the oxidation of firefly luciferin, which produces a   
short-lived flash of light that decays within a few seconds. However, the sensitivity of the luciferase 
assay is significantly higher than the CAT assay [6]. The high sensitivity of luciferase-based 
bioluminescence assays is better suited to HTS platforms than CAT or β-Gal assays. Moreover, various 
luciferase substrates are available that have a long half-life and provide linear results over eight orders 
of magnitude [4]. The enzyme has also been used in a dual-luciferase reporter assay system, which 
allows both firefly and sea pansy luciferase reactions to be monitored independently in the same  
cell [7]. This enables the activation of two different signaling pathways to be measured simultaneously 
in response to the same stimulus. 
2.4. Green Fluorescent Protein 
Rather than being a reporter enzyme, green fluorescent protein (GFP) (and its engineered 
derivatives) is particularly suited to bioimaging assays in living cells or live animals. GFP is produced 
by the jellyfish, Aequorea victoria. Upon excitation by UV light, GFP emits green light with an 
emission maximum at 509 nm [4]. The intensity of light emissions has been improved by protein 
engineering in the fluorophore region of the protein. GFP-based reporter assays provide a distinct 
advantage because they do not require cell permeabilization or the addition of exogenous substrates. 
Therefore, these proteins are suitable for drug screening in HTS assays. Recent improvements in GFP 
detection technologies allow changes in the localization of GFP-tagged proteins, in response to small 
molecules, to be detected at the subcellular level in living cells cultured in 384-well plates. Therefore, 
GFP is suitable as both a reporter of transcriptional activation, and of functional protein translocation 
in the cell, in response to various stimuli. Sensors 2012, 12  
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3. Extra-Cellular Reporters 
3.1. Secreted Alkaline Phosphatase (SEAP) 
The secreted alkaline phosphatase (SEAP) reporter system has been used to investigate the activity 
of known or putative promoter/enhancer elements [8]. As a reporter, SEAP has several important 
advantages over other reporters, such as high sensitivity and specificity both in vitro and in vivo [9–12]. 
SEAP is a C-terminal truncated mutant of the membrane-anchored, placental alkaline phosphatase [13]. 
Removal of the anchoring domain results in secretion of the enzyme into the culture medium or blood 
stream, thus enabling repeated sampling from living cells or animals. Expression of the gene can be 
detected using chemiluminometry [14]. The secreted form of alkaline phosphatase is extremely heat 
stable, and its activity can be detected following the inactivation of endogenous alkaline phosphatases 
by heating. Therefore, it is easy to distinguish between exogenous and endogenous SEAP activity. 
SEAP assays can also be coupled to a luciferase reaction by incubation with the substrate, firefly  
D-luciferin-O-phosphate. The product of the first reaction, luciferin, then becomes a substrate for 
luciferase. This assay protocol improves the sensitivity of the reporter assay system, thus enabling its 
broader application [15]. 
3.2. Secreted luciferase 
A recently-identified secreted form of luciferase also serves as a useful reporter for HTS assays. 
Luciferase from the marine copepod, Metridia longa, has unique secretary features that make it 
suitable for extracellular reporter assays. Markova et al. reported the substrate specificity of Metridia 
luciferase (MetLuc) and demonstrated its suitability for use as a reporter for monitoring gene 
expression [16]. In common with SEAP, secreted MetLuc is well suited to monitoring gene expression 
in time-course reporter assays. Both SEAP and MetLuc are currently available in a commercial dual 
reporter system that has been successfully applied in drug screening research [17–20]. 
4. Phenotypic Screening 
Reporter assay systems are suitable for the multi-parameter phenotype screening of drug   
candidates [21]. In contrast to the single molecular target approach, cell-based reporter assays reflect 
the complexity of the living organism. Therefore, they are becoming widely used to screen the effects 
of small molecules on signaling pathways [22]. However, drug discovery by HTS in cell-based assays 
presents its own difficulties. For instance, isolation of a hit compound often does not suggest a single, 
particular molecular target, preventing further optimization of hit compounds by medicinal   
chemistry [23]. This has led to cell-based screens being termed ‘black-box’ screens [21]. However, in 
most cases, target pathways may be predicted and investigated further. Nonetheless, drug companies 
prefer the well-characterized molecular target approach rather than phenotypic screening to accelerate 
the early phase of drug development. In fact, cell-based screens tend to identify more false positives 
than molecular target screens, presumably because of the existence of many potential targets in the 
biological pathway of interest [24]. Nonetheless, hit compounds from molecular target screens can fail 
to generate the expected effect on cells or have undesirable side effects that are potentially harmful to Sensors 2012, 12  
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humans. In the context of the ongoing paradigm shift towards pathway-driven drug discovery, 
particularly in the academic field, it becomes increasingly important to accomplish promising 
candidate isolation earlier in the drug discovery pipeline and with higher throughput. Currently, many 
large pharmaceutical companies have established open innovation research programs through 
collaboration with non-profit research organizations to overcome these problems. Academic research 
teams typically utilize cell-based reporter assay systems for primary drug screening. Furthermore, 
research is also being conducted using living animals to monitor the more complex dynamics of the hit 
compounds identified by screening. 
5. In Vivo Reporter Assays Using Mice 
Animal-based reporter assays using reporter mice are a potentially powerful tool for the identification 
of drug candidates. To our knowledge, the ERE–Luc (estrogen responsive element–luciferase gene) 
mouse is the first example of a reporter animal to be used for drug development [25], although several 
studies with simple reporter mice have been documented previously [26–28]. The ERE–Luc model is a 
unique reporter animal for drug discovery that was developed to identify ligands that bind estrogen 
receptors (ERs). Because ERs are ubiquitously expressed in mammals, this mouse model was required 
to be generally applicable to the activity of ERs [29]. 
Validation of the animal model is important to establish whether the reporter activity correlates with 
receptor activation through the targeted pathways. Nonetheless, the ERE–Luc mouse demonstrated the 
existence of unliganded activation of ERs [30]. Thus, animal-based reporter assays may provide new 
insights into the physiology of target pathways. Indeed, the use of the reporter mice revealed differential 
mechanisms of ER activation in reproductive and non-reproductive tissues [31]. These results indicate 
that reporter mice are useful for biological research. Precise toxicology studies may also be performed 
by crossing another mouse model, such as the humanized liver metabolism model, with reporter   
mice [32]. Such studies might require that the high costs of compound provision are met, and that 
animal welfare conditions are appropriate. Table 1 summarizes the properties of reporter proteins. 
Table 1. Properties of reporter proteins. 
 Specificity 
Application to
HTS 
Time-course 
Assay 
1 
In vivo 
Assay 
2 
Specific 
Tissue 
3 
Sensitivity to 
CCD camera 
4 
CAT B  C  C  C C  C 
β-Gal B  C  C  C C  C 
Luciferase A  A  B  B  A  A 
GFP A  A  B  B A  B 
SEAP A  A  A  A  B  A 
MetLuc A  A  A  A  B  A 
A: suitable, B: applicable, C: not applicable. 
1 Time-course assay is suitable for extra-cellular 
reporters compared to intra-cellular reporters. 
2 An in vivo imaging system is needed to detect 
luciferase and GFP. 
3 A tissue specific transgenic mouse is needed to detect specific tissue 
expression of extra-cellular reporters. 
4 Chemiluminescence is more sensitive than fluorescence. 
CAT: Chloramphenicol acetyltransferase; β-Gal: β-Galactosidase; GFP: green fluorescent protein; 
SEAP: secreted alkaline phosphatase; MetLuc: Metridia longa luciferase; HTS: high throughput 
screening; CCD: charge-coupled device. Sensors 2012, 12  
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6. Screening of Anti-Aging Drugs That Mimic the Beneficial Effects of Calorie Restriction 
Calorie restriction (CR) extends the lifespan of many organisms [33]. The identification of CR 
mimetic compounds may therefore enable therapeutic retardation of the onset of various age-related 
disorders, including metabolic syndrome, cancers, neurodegenerative diseases, and other rare   
disorders [34]. The development of CR mimetics would therefore fulfill unmet medical needs. 
Although SIRT1-activating compounds (STACs) may offer a promising approach to the development 
of CR mimetics, a novel approach to finding potential CR mimetics is required [9]. For this purpose, 
we developed a cell- and mouse-based screening system using an extracellular reporter assay [10]. 
Using microarray analysis, we have identified putative regulatory elements in pro-longevity genes 
(dwarfism and CR-response elements: DFCR-RE) [9,35]. Using one of the DFCR-REs, we have 
developed a cell- and animal-based reporter screening system, named CRISP: the CR-Imitating   
anti-aging agent Screening Platform. Because the DFCR-REs were isolated from long-lived mice, the 
unidentified transcriptional regulators of this sequence may be beneficial for longevity and delay the 
onset of age-related diseases. We found that reporter construct transgenic mice (CRISP mice) showed 
increased reporter activity upon CR ([9] and our unpublished data). Hence, compounds that activate 
this reporter may be CR mimetic pro-longevity drug candidates. As revealed in the ERE-Luc mice, 
CRISP mice may also reveal novel longevity signaling pathways and target molecules. The activity of 
candidate compounds can be easily studied on cells by their addition to culture medium, or in mice by 
their addition to food and water. In addition to isolating the activators of pro-longevity elements, our 
CRISP method may also identify inhibitors or negative regulators of these elements. In this respect, 
CRISP is advantageous compared to single molecular target screening. Therefore, a two-step screen in 
which a primary HTS in CRISP cells is used to identify hit compounds, followed by a secondary 
screen to verify the activity, metabolism and toxicology of the hits in CRISP mice, is a potentially 
powerful tool for identifying promising novel drug candidates. 
7. Conclusions 
Current reporter assay technologies enabled us to perform high throughput screening of chemical 
libraries. The isolation of candidate molecules is dependent on the choice of reporter protein and the 
construction of efficient cell- or animal-based assays. The identification of CR mimetics is attractive 
for the development of anti-aging therapeutics. While CR mimetics may not be a ‘cure-all’ for age-
associated disorders, they may suppress and/or delay the progression of various kinds of refractory 
diseases. Importantly, pharmaceutical companies do not have a high incentive to develop drugs for rare 
diseases. Therefore, academic laboratories are perfectly placed to develop drugs for rare disorders by 
using phenotypic cell- or animal-based reporter assay systems. Although candidate CR mimetics 
identified in such systems must still be validated to show that their beneficial effects are similar to 
those provided by CR, CR mimetics offer great potential to solve the unmet medical needs of rare 
diseases and common age-related disorders. We have focused on bioassay (protein reporter assay) 
screening systems in this review, but biosensor technologies (analytical devices consisting of biological 
components) are also important for drug discovery [36]. Therefore, the development of biosensors to 
screen CR mimetics will also be an important approach to future drug discovery efforts. Sensors 2012, 12  
 
 
1654
Acknowledgments 
This work was supported by grants to T. Chiba from the 2012 Danone Institute of Japan Foundation 
(DIJF) Research Grant, the Adaptable & Seamless Technology Transfer Program through Target-driven 
R&D (A-STEP) of the Japan Science and Technology Agency (FS stage, Exploratory Research: 
AS231Z00030F), Takeda Science Foundation, and Nagasaki University. 
References 
1.  Bronstein, I.; Fortin, J.; Stanley, P.E.; Stewart, G.S.; Kricka, L.J. Chemiluminescent and 
bioluminescent reporter gene assays. Anal. Biochem. 1994, 219, 169–181. 
2.  Deo, S.K.; Daunert, S. Luminescent proteins from Aequorea victoria: Applications in drug 
discovery and in high throughput analysis. Fresenius J. Anal. Chem. 2001, 369, 258–266. 
3.  Hill, S.J.; Baker, J.G.; Rees, S. Reporter-gene systems for the study of G-protein-coupled 
receptors. Curr. Opin. Pharmacol. 2001, 1, 526–532. 
4.  New, D.C.; Miller-Martini, D.M.; Wong, Y.H. Reporter gene assays and their applications to 
bioassays of natural products. Phytother. Res. 2003, 17, 439–448. 
5.  Gorman, C.M.; Moffat, L.F.; Howard, B.H. Recombinant genomes which express chloramphenicol 
acetyltransferase in mammalian cells. Mol. Cell Biol. 1982, 2, 1044–1051. 
6.  Alam, J.; Cook, J.L. Reporter genes: Application to the study of mammalian gene transcription. 
Anal. Biochem. 1990, 188, 245–254. 
7.  Stables, J.; Scott, S.; Brown, S.; Roelant, C.; Burns, D.; Lee, M.G.; Rees, S. Development of a 
dual glow-signal firefly and Renilla luciferase assay reagent for the analysis of G-protein coupled 
receptor signalling. J. Recept. Signal Transduct. Res. 1999, 19, 395–410. 
8.  Berger, J.; Hauber, J.; Hauber, R.; Geiger, R.; Cullen, B.R. Secreted placental alkaline 
phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 
1988, 66, 1–10. 
9.  Chiba, T.; Tsuchiya, T.; Komatsu, T.; Mori, R.; Hayashi, H.; Shimano, H.; Spindler, S.R.; 
Shimokawa, I. Development of a bioassay to screen for chemicals mimicking the anti-aging 
effects of calorie restriction. Biochem. Biophys. Res. Commun. 2010, 401, 213–218.  
10. Chiba, T.; Tsuchiya, T.; Komatsu, T.; Mori, R.; Hayashi, H.; Shimokawa, I. Development   
of calorie restriction mimetics as therapeutics for obesity, diabetes, inflammatory and 
neurodegenerative diseases. Curr. Genomics 2010, 11, 562–567. 
11. Hiramatsu, N.; Kasai, A.; Hayakawa, K.; Yao, J.; Kitamura, M. Real-time detection and 
continuous monitoring of ER stress in vitro and in vivo by ES-TRAP: Evidence for systemic, 
transient ER stress during endotoxemia. Nucleic Acids Res. 2006, 34, doi:10.1093/nar/gkl515. 
12.  Kasai, A.; Hiramatsu, N.; Meng, Y.; Yao, J.; Takeda, M.; Maeda, S.; Kitamura, M. DRESSA: 
Biosensing of dioxin and dioxin-like chemicals using secreted alkaline phosphatase. Anal. 
Biochem. 2004, 335, 73–80. 
13.  Cullen, B.R.; Malim, M.H. Secreted placental alkaline phosphatase as a eukaryotic reporter gene. 
Methods Enzymol. 1992, 216, 362–368. Sensors 2012, 12  
 
 
1655
14. Bronstein, I.; Fortin, J.J.; Voyta, J.C.; Juo, R.R.; Edwards, B.; Olesen, C.E.; Lijam, N.;   
Kricka, L.J. Chemiluminescent reporter gene assays: Sensitive detection of the GUS and SEAP 
gene products. Biotechniques 1994, 17, 172–174. 
15. Miska, W.; Geiger, R. Synthesis and characterization of luciferin derivatives for use in 
bioluminescence enhanced enzyme immunoassays. New ultrasensitive detection systems for 
enzyme immunoassays, I. J. Clin. Chem. Clin. Biochem. 1987, 25, 23–30. 
16.  Markova, S.V.; Golz, S.; Frank, L.A.; Kalthof, B.; Vysotski, E.S. Cloning and expression of 
cDNA for a luciferase from the marine copepod Metridia longa. A novel secreted bioluminescent 
reporter enzyme. J. Biol. Chem. 2004, 279, 3212–3217. 
17.  Junker, L.M.; Clardy, J. High-throughput screens for small-molecule inhibitors of Pseudomonas 
aeruginosa biofilm development. Antimicrob. Agents Chemother. 2007, 51, 3582–3590. 
18.  Lynch, R.A.; Etchin, J.; Battle, T.E.; Frank, D.A. A small-molecule enhancer of signal transducer 
and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of 
IFN-gamma in human cancer cells. Cancer Res. 2007, 67, 1254–1261. 
19.  Rossi, C.; Padmanaban, D.; Ni, J.; Yeh, L.A.; Glicksman, M.A.; Waldner, H. Identifying druglike 
inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule 
library. J. Biomol. Screen. 2007, 12, 481–489. 
20.  Severson, W.E.; Shindo, N.; Sosa, M.; Fletcher, T., 3rd; White, E.L.; Ananthan, S.; Jonsson, C.B. 
Development and validation of a high-throughput screen for inhibitors of SARS CoV and its 
application in screening of a 100,000-compound library. J. Biomol. Screen. 2007, 12, 33–40. 
21.  Feng, Y.; Mitchison, T.J.; Bender, A.; Young, D.W.; Tallarico, J.A. Multi-parameter phenotypic 
profiling: Using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 
2009, 8, 567–578. 
22.  Fishman, M.C.; Porter, J.A. Pharmaceuticals: A new grammar for drug discovery. Nature 2005, 
437, 491–493. 
23.  Hart, C.P. Finding the target after screening the phenotype. Drug Discov. Today 2005, 10, 513–519. 
24. Crisman, T.J. Parker, C.N.; Jenkins, J.L.; Scheiber, J.; Thoma, M.; Kang, Z.B.; Kim, R.;   
Bender, A.; Nettles, J.H.; Davies, J.W.; et al. Understanding false positives in reporter gene 
assays: In silico chemogenomics approaches to prioritize cell-based HTS data. J. Chem. Inf. 
Model. 2007, 47, 1319–1327. 
25.  Nagel, S.C.; Hagelbarger, J.L.; McDonnell, D.P. Development of an ER action indicator mouse 
for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. Endocrinology 
2001, 142, 4721–4728. 
26.  Balkan, W.; Colbert, M.; Bock, C.; Linney, E. Transgenic indicator mice for studying activated 
retinoic acid receptors during development. Proc. Natl. Acad. Sci. USA 1992, 89, 3347–3351. 
27.  Montoliu, L.; Blendy, J.A.; Cole, T.J.; Schutz, G. Analysis of perinatal gene expression: Hormone 
response elements mediate activation of a lacZ reporter gene in liver of transgenic mice. Proc. 
Natl. Acad. Sci. USA 1995, 92, 4244–4248. 
28.  Rossant, J.; Zirngibl, R.; Cado, D.; Shago, M.; Giguere, V. Expression of a retinoic acid response 
element-hsplacZ transgene defines specific domains of transcriptional activity during mouse 
embryogenesis. Genes Dev. 1991, 5, 1333–1344. Sensors 2012, 12  
 
 
1656
29.  Maggi, A.; Ottobrini, L.; Biserni, A.; Lucignani, G.; Ciana, P. Techniques: Reporter mice—A new 
way to look at drug action. Trends Pharmacol. Sci. 2004, 25, 337–342. 
30. Klotz, D.M.; Hewitt, S.C.; Ciana, P.; Raviscioni, M.; Lindzey, J.K.; Foley, J.; Maggi, A.; 
DiAugustine, R.P.; Korach, K.S. Requirement of estrogen receptor-alpha in insulin-like growth 
factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor 
cross-talk. J. Biol. Chem. 2002, 277, 8531–8537. 
31.  Ciana, P.; Raviscioni, M.; Mussi, P.; Vegeto, E.; Que, I.; Parker, M.G.; Lowik, C.; Maggi, A.  
In vivo imaging of transcriptionally active estrogen receptors. Nat. Med. 2003, 9, 82–86. 
32.  Xie, W.; Evans, R.M. Pharmaceutical use of mouse models humanized for the xenobiotic receptor. 
Drug Discov. Today 2002, 7, 509–515. 
33. Masoro, E.J.; Shimokawa, I.; Yu, B.P. Retardation of the aging processes in rats by food 
restriction. Ann. N. Y. Acad. Sci. 1991, 621, 337–352. 
34.  Schiff, M.; Benit, P.; Coulibaly, A.; Loublier, S.; El-Khoury, R.; Rustin, P. Mitochondrial response 
to controlled nutrition in health and disease. Nutr. Rev. 2011, 69, 65–75. 
35.  Tsuchiya, T.; Dhahbi, J.M.; Cui, X.; Mote, P.L.; Bartke, A.; Spindler, S.R. Additive regulation  
of hepatic gene expression by dwarfism and caloric restriction. Physiol. Genomics 2004,  17,  
307–315. 
36. Keusgen, M. Biosensors: New approaches in drug discovery. Naturwissenschaften  2002,  89,  
433–444. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 